Tuberculosis treatment is a protracted process that often necessitates the combined use of multiple anti-tuberculosis drugs over an extended period.This prolonged and complex treatment regimen can give rise to a range of adverse drug reactions that may affect various bodily systems and differ in severity.Notably,hematological abnormalities are among the more prevalent side effects observed.Clinical data indicates a significant incidence of thrombocytopenia following the administration of anti-tuberculosis medications,elevating the risk of bleeding in patients.In extreme cases,bleeding in crucial organs can pose a grave threat to life.Herein,we detail a fatal instance of profound thrombocytopenia,complicated by severe cerebral hemorrhage,that arose during a quadruplex anti-tuberculosis treatment course comprising rifampicin,pyrazinamide,ethambutol,and isoniazid.Furthermore,we undertake a review of pertinent literature and delve into potential treatment strategies for such cases,with the ultimate goal of emphasizing the critical need for clinicians to closely monitor thrombocytopenia induced by anti-tuberculosis drugs and prioritize patient safety throughout the course of medication.
维普
万方数据